V101L of human formyl peptide receptor 1 (FPR1) increases receptor affinity and augments the antagonism mediated by cyclosporins

Biochemical Journal

Volumn 451, Issue 2, 2013, Pages 245-255

  Zhou, Caihong ^a,b   Zhou, Yan ^a   Wang, Jia ^a   Feng, Yang ^a   Wang, Haonan ^a   Xue, Jinglun ^b   Chen, Yani ^c   Ye, Richard D ^d   Wang, Ming Wei ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b FUDAN UNIVERSITY   (China)

^c Shanghai ADICON Clinical Laboratories   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cyclosporin; Formyl peptide receptor 1 (FPR1); Haplotype; Pharmacogenomics; Receptor affinity; Single nucleotide polymorphism

Indexed keywords

CALCIUM; COMPLEMENTARY DNA; CYCLOSPORIN A; CYCLOSPORIN H; FORMYL PEPTIDE RECEPTOR 1; FORMYLPEPTIDE RECEPTOR; LEUCINE; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CALCIUM MOBILIZATION; CHINESE; CONTROLLED STUDY; DRUG ANTAGONISM; FEMALE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SINGLE NUCLEOTIDE POLYMORPHISM;

AMINO ACID SUBSTITUTION; ANIMALS; ASIAN CONTINENTAL ANCESTRY GROUP; CALCIUM; CHEMOTAXIS; CHO CELLS; CRICETINAE; CRICETULUS; CYCLOSPORINE; CYCLOSPORINS; FEMALE; HAPLOTYPES; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 3; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, FORMYL PEPTIDE;

EID: 84875635725     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20121839     Document Type: Article

References (36)

1. Salari, K., Watkins, H. and Ashley, E. A. (2012) Personalized medicine: hope or hype Eur. Heart J. 33, 1564-1570
2. Madian, A. G., Wheeler, H. E., Jones, R. B. and Dolan, M. E. (2012) Relating human genetic variation to variation in drug responses. Trends Genet. 28, 487-495
3. Amatruda, 3rd, T. T., Dragas-Graonic, S., Holmes, R. and Perez, H. D. (1995) Signal transduction by the formyl peptide receptor. Studies using chimeric receptors and site-directed mutagenesis define a novel domain for interaction with G-proteins. J. Biol. Chem. 270, 28010-28013
4. di Iulio, J. and Rotger, M. (2011) Pharmacogenomics: what is next Front. Pharmacol. 2, 86
5. Hamburg, M. A. and Collins, F. S. (2010) The path to personalized medicine. New Engl. J. Med. 363, 301-304
6. Ruegger, A., Kuhn, M., Lichti, H., Loosli, H. R., Huguenin, R., Quiquerez, C. and von Wartburg, A. (1976) Cyclosporin A, a peptide metabolite from Trichoderma polysporum (Link ex Pers.) rifai, with a remarkable immunosuppressive activity. Helv. Chim. Acta 59, 1075-1092
7. Liu, J., Farmer, Jr., J. D., Lane, W. S., Friedman, J., Weissman, I. and Schreiber, S. L. (1991) Calcineurin is a common target of cyclophilin- cyclosporin A and FKBP-FK506 complexes. Cell 66, 807-815
8. Wenger, R. M., France, J., Bovermann, G., Walliser, L., Widmer, A. and Widmer, H. (1994) The 3D structure of a cyclosporin analogue in water is nearly identical to the cyclophilin-bound cyclosporin conformation. FEBS Lett. 340, 255-259
9. Loor, F., Tiberghien, F., Wenandy, T., Didier, A. and Traber, R. (2002) Cyclosporins: structure-activity relationships for the inhibition of the human FPR1 formylpeptide receptor. J. Med. Chem. 45, 4613-4628
10. Giaccone, G., Linn, S. C., Welink, J., Catimel, G., Stieltjes, H., van der Vijgh, W. J., Eeltink, C., Vermorken, J. B. and Pinedo, H. M. (1997) A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin. Cancer Res. 3, 2005-2015
11. Gonzalez, O., Colombo, T., De Fusco, M., Imperatori, L., Zucchetti, M. and D'Incalci, M. (1995) Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother. Pharmacol. 36, 335-340
12. Yan, P., Nanamori, M., Sun, M., Zhou, C., Cheng, N., Li, N., Zheng, W., Xiao, L., Xie, X., Ye, R. D. and Wang, M. W. (2006) The immunosuppressant cyclosporin A antagonizes human formyl peptide receptor through inhibition of cognate ligand binding. J. Immunol. 177, 7050-7058
13. Ye, R. D., Boulay, F., Wang, J. M., Dahlgren, C., Gerard, C., Parmentier, M., Serhan, C. N. and Murphy, P. M. (2009) International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61, 119-161
14. Brookes, A. J. (1999) The essence of SNPs. Gene 234, 177-186
15. Cargill, M., Altshuler, D., Ireland, J., Sklar, P., Ardlie, K., Patil, N., Shaw, N., Lane, C. R., Lim, E. P., Kalyanaraman, N. et al. (1999) Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat. Genet. 22, 231-238
16. Sahagun-Ruiz, A., Colla, J. S., Juhn, J., Gao, J. L., Murphy, P. M. and McDermott, D. H. (2001) Contrasting evolution of the human leukocyte N-formylpeptide receptor subtypes FPR and FPRL1R. Genes Immun. 2, 335-342
17. Rabiet, M. J., Huet, E. and Boulay, F. (2005) Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur. J. Immunol. 35, 2486-2495
18. Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., Brohi, K., Itagaki, K. and Hauser, C. J. (2010) Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464, 104-107
19. Sun, R., Iribarren, P., Zhang, N., Zhou, Y., Gong, W., Cho, E. H., Lockett, S., Chertov, O., Bednar, F., Rogers, T. J. et al. (2004) Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor. J. Immunol. 173, 428-436
20. Lin, Q., Fang, D., Hou, X., Le, Y., Fang, J., Wen, F., Gong, W., Chen, K., Wang, J. M. and Su, S. B. (2011) HCV peptide (C5A), an amphipathic α-helical peptide of hepatitis virus C, is an activator of N-formyl peptide receptor in human phagocytes. J. Immunol. 186, 2087-2094
21. Su, S. B., Gong, W. H., Gao, J. L., Shen, W. P., Grimm, M. C., Deng, X., Murphy, P. M., Oppenheim, J. J. and Wang, J. M. (1999) T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor. Blood 93, 3885-3892
22. Su, S. B., Gao, J., Gong, W., Dunlop, N. M., Murphy, P. M., Oppenheim, J. J. and Wang, J. M. (1999) T21/DP107, a synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors. J. Immunol. 162, 5924-5930
23. Gao, J. L., Lee, E. J. and Murphy, P. M. (1999) Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor. J. Exp. Med. 189, 657-662
24. Clark, R. A., Page, R. C. and Wilde, G. (1977) Defective neutrophil chemotaxis in juvenile periodontitis. Infect. Immun. 18, 694-700
25. Zhang, Y., Syed, R., Uygar, C., Pallos, D., Gorry, M. C., Firatli, E., Cortelli, J. R., VanDyke, T. E., Hart, P. S., Feingold, E. and Hart, T. C. (2003) Evaluation of human leukocyte N-formylpeptide receptor (FPR1) SNPs in aggressive periodontitis patients. Genes Immun. 4, 22-29
26. Gwinn, M. R., Sharma, A. and De Nardin, E. (1999) Single nucleotide polymorphisms of the N-formyl peptide receptor in localized juvenile periodontitis. J. Periodontol. 70, 1194-1201
27. Gunji, T., Onouchi, Y., Nagasawa, T., Katagiri, S., Watanabe, H., Kobayashi, H., Arakawa, S., Noguchi, K., Hata, A., Izumi, Y. and Ishikawa, I. (2007) Functional polymorphisms of the FPR1 gene and aggressive periodontitis in Japanese. Biochem. Biophys. Res. Commun. 364, 7-13
28. Maney, P., Emecen, P., Mills, J. S. and Walters, J. D. (2009) Neutrophil formylpeptide receptor single nucleotide polymorphism 348T>C in aggressive periodontitis. J. Periodontol. 80, 492-498
29. El Shamieh, S., Herbeth, B., Azimi-Nezhad, M., Benachour, H., Masson, C. and Visvikis-Siest, S. (2012) Human formyl peptide receptor 1 C32T SNP interacts with age and is associated with blood pressure levels. Clin. Chim. Acta 413, 34-38
30. Gripentrog, J. M., Mills, J. S., Saari, G. J. and Miettinen, H. M. (2008) Variable responses of formyl peptide receptor haplotypes toward bacterial peptides. Immunogenetics 60, 83-93
31. He, R., Tan, L., Browning, D. D., Wang, J. M. and Ye, R. D. (2000) The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor. J. Immunol. 165, 4598-4605
32. Li, Z., Zhang, Z., He, Z., Tang, W., Li, T., Zeng, Z., He, L. and Shi, Y. (2009) A partitionligation- combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio- x.cn). Cell Res. 19, 519-523
33. Zhou, C., Zhang, S., Nanamori, M., Zhang, Y., Liu, Q., Li, N., Sun, M., Tian, J., Ye, P. P., Cheng, N. et al. (2007) Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1. Mol. Pharmacol. 72, 976-983
34. Gabriel, S. B., Schaffner, S. F., Nguyen, H., Moore, J. M., Roy, J., Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A., Faggart, M. et al. (2002) The structure of haplotype blocks in the human genome. Science 296, 2225-2229
35. Benachour, H., Zaiou, M., Herbeth, B., Lambert, D., Lamont, J. V., Pfister, M., Siest, G., Tiret, L., Blankenberg, S., Fitzgerald, P. S. and Visvikis-Siest, S. (2009) Human formyl peptide receptor 1 (FPR1) c.32C>T SNP is associated with decreased soluble E-selectin levels. Pharmacogenomics 10, 951-959
36. Le, Y., Murphy, P. M. and Wang, J. M. (2002) Formyl-peptide receptors revisited. Trends Immunol. 23, 541-548